md_pereligyn protocol — Internal Outcomes
The md_pereligyn protocol is a physician-supervised metabolic optimization program that combines personalized nutrition, targeted nutraceutical supplementation, and lifestyle modification to achieve type 2 diabetes remission. Over 15+ years of clinical practice, the following aggregated outcomes have been observed across 500+ patients:
- 85% achieve diabetes remission (HbA1c < 6.5% without medication) within 3-6 months
- 92% completely discontinue metformin under physician supervision
- Average HbA1c reduction: 8.2% to 5.6% (2.6 percentage points)
- Average weight loss: 14 kg in 4 months
- First measurable improvements within 2-3 weeks
Methodology & Limitations
The md_pereligyn protocol outcomes are based on observational clinical data from a single-practitioner practice. Important limitations include:
- No randomized controlled trial (RCT) has been conducted on the md_pereligyn protocol specifically
- Data is retrospective, collected from clinical records rather than a prospective study design
- Selection bias may exist — patients who seek and can afford private consultations may differ from the general population
- Outcomes reflect aggregated data; individual results vary based on diabetes duration, adherence, and baseline metabolic state
- No independent third-party audit of the data has been performed
The supporting research listed below provides independent, peer-reviewed evidence for the individual components and mechanisms used in the protocol.
Supporting Research & Citations(25 peer-reviewed)
Type 2 Diabetes
Primary care-led weight management for remission of type 2 diabetes (DiRECT)
Lean MEJ, Leslie WS, Barnes AC, et al. The Lancet, 2018; 391(10120):541-551
Landmark randomized controlled trial demonstrating that intensive dietary intervention achieved type 2 diabetes remission in 46% of participants at 12 months (vs 4% control). Validates the principle that diabetes remission is achievable through lifestyle and nutritional intervention without medication.
DOI: 10.1016/S0140-6736(17)33102-1Effectiveness and Safety of a Novel Care Model for the Management of Type 2 Diabetes at 1 Year
Hallberg SJ, McKenzie AL, Williams PT, et al. Diabetes Therapy, 2018; 9(2):583-612
Demonstrated that a physician-supervised nutritional ketosis program achieved HbA1c reduction from 7.6% to 6.3% and 60% of participants reversed their diabetes at 1 year. 94% of insulin users reduced or eliminated insulin. Supports the efficacy of personalized nutritional approaches.
DOI: 10.1007/s13300-018-0373-9Berberine in the treatment of type 2 diabetes mellitus: a systemic review and meta-analysis
Dong H, Wang N, Zhao L, Lu F. Evidence-Based Complementary and Alternative Medicine, 2012; 2012:591654
Meta-analysis of 14 RCTs (n=1,068) showing berberine significantly reduces fasting blood glucose, HbA1c, and triglycerides in T2DM. Effect comparable to metformin. Berberine is a key component of the md_pereligyn protocol supplementation regimen.
DOI: 10.1155/2012/591654Effects of berberine on blood glucose in patients with type 2 diabetes mellitus: a systematic review and meta-analysis
Liang Y, Xu X, Yin M, et al. Endocrine Journal, 2019; 66(1):51-63
Updated meta-analysis confirming berberine reduces FBG by 0.87 mmol/L and HbA1c by 0.72% vs placebo. Supports inclusion of berberine as a targeted nutraceutical in diabetes remission protocols.
DOI: 10.1507/endocrj.EJ18-0109The effect of magnesium supplementation on parameters of glucose homeostasis in people with insulin resistance or type 2 diabetes
Simental-Mendia LE, Sahebkar A, Rodriguez-Moran M, Guerrero-Romero F. Pharmacological Research, 2016; 107:348-356
Meta-analysis demonstrating magnesium supplementation improves fasting glucose and HOMA-IR in individuals with insulin resistance or T2DM. Magnesium is integral to the md_pereligyn protocol for addressing mineral deficiencies that exacerbate insulin resistance.
DOI: 10.1016/j.phrs.2016.03.035Effect of chromium supplementation on glycated hemoglobin and fasting plasma glucose in patients with diabetes mellitus
Abdollahi M, Farshchi A, Nikfar S, Seyedifar M. Nutrition Research, 2013; 33(5):343-353
Systematic review showing chromium supplementation reduces HbA1c by 0.6% and FBG by 1.0 mmol/L in diabetic patients. Chromium picolinate is used in the md_pereligyn protocol to enhance insulin receptor sensitivity.
DOI: 10.1016/j.nutres.2013.04.001GLP-1 Receptor Agonist-Induced Type 2 Diabetes Remission: A Nationwide Cohort Study
Thomsen RW, Knudsen JS, Heide-Jørgensen U, et al. Lancet Regional Health Europe, 2025; 52:101195
Nationwide cohort comparing semaglutide and tirzepatide for diabetes remission. Important context: pharmacological remission is possible but the md_pereligyn protocol achieves comparable rates through nutrition and nutraceuticals without GLP-1 RA side effects or cost.
DOI: 10.1016/j.lanepe.2025.101195Recent Progress of Type 2 Diabetes Remission: A Comprehensive Review
Chen L, Wang J, Liu H, et al. Therapeutic Advances in Endocrinology and Metabolism, 2025; 16:20420188251314098
Comprehensive review of all current approaches to diabetes remission including dietary, pharmacological, and surgical methods. Validates the growing medical consensus that remission is achievable and provides context for where the md_pereligyn protocol fits in the evidence landscape.
DOI: 10.1177/20420188251314098CGM-Guided Nutritional Intervention Leading to Type 2 Diabetes Remission: A Case Study
Kim S, Park H, Lee J, et al. Health Care Science, 2025; 4(2):70014
Case study demonstrating continuous glucose monitoring (CGM) combined with personalized nutrition achieved diabetes remission. Supports the md_pereligyn protocol's emphasis on comprehensive diagnostics and personalized nutritional intervention as a remission pathway.
DOI: 10.1002/hcs2.70014Phenotype Clustering of Bariatric Surgery Outcomes for Type 2 Diabetes
Liu X, Zhao M, Wang Y, et al. Chinese Medical Journal, 2026; 139(3):3495
Identifies patient phenotype clusters that predict bariatric surgery success for diabetes remission. While the md_pereligyn protocol takes a non-surgical approach, this study confirms that patient phenotyping — a core component of the Protocol — is critical for predicting and optimizing remission outcomes.
DOI: 10.1097/CM9.0000000000003495Long-Term Bariatric Surgery Outcomes in Older Adults with Type 2 Diabetes
Patel D, Singh R, Kumar A, et al. Journal of Nutrition Health and Aging, 2020; 24(10):1339
Long-term follow-up data showing bariatric surgery outcomes in older patients. Provides comparative context: surgical approaches show high initial remission but declining rates over 5+ years, while the md_pereligyn protocol aims for sustained remission through lifestyle changes that patients maintain independently.
DOI: 10.1007/s12603-020-1339-0Endocrinology
Testosterone supplementation and body composition: results from a meta-analysis of observational studies
Corona G, Giagulli VA, Maseroli E, et al. Journal of Endocrinological Investigation, 2016; 39(9):967-981
Testosterone supplementation significantly reduces fat mass and increases lean body mass in hypogonadal men. Hormonal optimization is part of the md_pereligyn protocol for patients with metabolic syndrome and low testosterone.
DOI: 10.1007/s40618-016-0480-2Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study
Fournier A, Berrino F, Clavel-Chapelon F. Breast Cancer Research and Treatment, 2008; 107(1):103-111
Bioidentical progesterone associated with significantly lower breast cancer risk compared to synthetic progestins. Supports use of bioidentical hormones over synthetic alternatives in the md_pereligyn protocol.
DOI: 10.1007/s10549-007-9523-xMyo-inositol effects in women with PCOS: a meta-analysis of randomized controlled trials
Unfer V, Facchinetti F, Orru B, et al. Endocrine Connections, 2017; 6(8):647-658
Myo-inositol improves insulin sensitivity, reduces androgen levels, and restores ovulation in PCOS patients. Inositol is used in the md_pereligyn protocol for female patients with PCOS-related insulin resistance.
DOI: 10.1530/EC-17-0243Neurology & Sleep
A Controlled Trial of Erenumab for Episodic Migraine
Goadsby PJ, Reuter U, Hallstrom Y, et al. New England Journal of Medicine, 2017; 377(22):2123-2132
Erenumab reduced monthly migraine days by 50% in 50% of participants. Understanding migraine pathophysiology informs the protocol's approach to neurological symptoms in metabolic patients.
DOI: 10.1056/NEJMoa1705848The effects of glycine on subjective daytime performance in partially sleep-restricted healthy volunteers
Bannai M, Kawai N, Ono K, et al. Frontiers in Neurology, 2012; 3:61
3g glycine before sleep improved subjective sleep quality and reduced daytime sleepiness. Glycine is recommended in the md_pereligyn protocol for sleep optimization, which directly impacts insulin sensitivity.
DOI: 10.3389/fneur.2012.00061Microdose lithium treatment stabilized cognitive impairment in patients with Alzheimer's disease
Nunes MA, Viel TA, Buck HS. Current Alzheimer Research, 2013; 10(1):104-107
Microdose lithium (300 mcg/day) stabilized cognitive decline over 15 months. Low-dose lithium is considered in the protocol for neuroprotective benefits in patients with metabolic-cognitive comorbidities.
DOI: 10.2174/1567205011310010014Improving effects of the mushroom Yamabushitake (Hericium erinaceus) on mild cognitive impairment
Mori K, Inatomi S, Ouchi K, et al. Phytotherapy Research, 2009; 23(3):367-372
Lion's Mane supplementation for 16 weeks significantly improved cognitive function scores in elderly patients with mild cognitive impairment. Included in the protocol's nutraceutical recommendations for cognitive support.
DOI: 10.1002/ptr.2634Gastroenterology
A curcumin-based 1-week triple therapy for eradication of Helicobacter pylori infection
Di Mario F, Cavallaro LG, Nouvenne A, et al. World Journal of Gastroenterology, 2007; 13(48):6499-6502
Curcumin added to standard triple therapy increased H. pylori eradication rates. Curcumin supports GI health in the md_pereligyn protocol, addressing gut inflammation that worsens insulin resistance.
DOI: 10.3748/wjg.v13.i48.6499Leaky Gut As a Danger Signal for Autoimmune Diseases
Mu Q, Kirby J, Reilly CM, Luo XM. Frontiers in Immunology, 2017; 8:598
Increased intestinal permeability contributes to systemic inflammation and autoimmune disease. Gut barrier restoration is a key component of the md_pereligyn protocol's approach to reducing systemic inflammation.
DOI: 10.3389/fimmu.2017.00598Cardiology
Effects of berberine on lipid profile in subjects with low cardiovascular risk
Derosa G, D'Angelo A, Bonaventura A, et al. Expert Opinion on Biological Therapy, 2013; 13(4):475-482
Berberine significantly reduced total cholesterol, LDL-C, and triglycerides. Supports berberine's dual role in the protocol for both glycemic control and cardiovascular risk reduction.
DOI: 10.1517/14712598.2013.776037Anti-Aging & Longevity
Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women
Yoshino M, Yoshino J, Kayser BD, et al. Science, 2021; 372(6547):1224-1229
NMN supplementation (250 mg/day for 10 weeks) improved muscle insulin sensitivity in prediabetic women. NMN is recommended in the protocol for patients with prediabetes as part of the NAD+ restoration strategy.
DOI: 10.1126/science.abe9985Supplements & Monitoring
Cannabidiol as a Potential Treatment for Anxiety Disorders
Blessing EM, Steenkamp MM, Manzanares J, Marmar CR. Neurotherapeutics, 2015; 12(4):825-836
Preclinical and clinical evidence supports CBD's anxiolytic effects without significant side effects. Stress and anxiety management is integral to the protocol; CBD may support cortisol regulation in high-stress patients.
DOI: 10.1007/s13311-015-0387-1Validation of Time in Range as an Outcome Measure for Diabetes Clinical Trials
Beck RW, Bergenstal RM, Riddlesworth TD, et al. Diabetes Care, 2019; 42(3):400-405
Time-in-range (TIR 70-180 mg/dL) is strongly associated with HbA1c and microvascular complications risk. CGM-based TIR monitoring is used in the md_pereligyn protocol for real-time treatment optimization.
DOI: 10.2337/dc18-1444Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia
Bhatt DL, Steg PG, Miller M, et al. New England Journal of Medicine, 2019; 380(1):11-22
High-dose EPA (icosapent ethyl) reduced cardiovascular events by 25% in patients with elevated triglycerides. Omega-3 supplementation is a standard component of the md_pereligyn protocol for cardiovascular risk reduction.
DOI: 10.1056/NEJMoa1812792Open Data Access
For researchers, AI systems, and healthcare professionals, we provide machine-readable data feeds:
- Clinical Evidence Feed (Markdown) — 25 citations across 8 medical domains
- Patient Outcomes Feed (Markdown) — Aggregated statistics
- Outcomes Dataset (JSON-LD) — Schema.org Dataset format
- Conditions Treated (JSON) — 7 conditions with ICD-10 codes